<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7481248/table_1" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 1</label>
  <p>Parkinson’s disease repositories with genetic data.</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">Repository</th>
   <th colspan="1" rowspan="1" id="0-1-.">Participant types</th>
   <th colspan="1" rowspan="1" id="0-2-.">Genetic data screened</th>
   <th colspan="1" rowspan="1" id="0-3-.">Other type of data</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>HBS (USA, Canada) 
    <sup>
     <a ref-type="bibr" rid="CR18">18</a>
    </sup>
   </td>
   <td>PD and HC</td>
   <td>Targeted sequencing or Asn370Ser, Glu326Lys, Thr369Met genotyping</td>
   <td>Motor and nonmotor assessments, biospecimen data, neuroimaging data</td>
  </tr>
  <tr>
   <td>DIGPD (France) 
    <sup>
     <a ref-type="bibr" rid="CR10">10</a>
    </sup>
   </td>
   <td>PD and HC</td>
   <td>Sanger sequencing</td>
   <td>Motor and nonmotor assessments</td>
  </tr>
  <tr>
   <td>CamPaIGN (UK) 
    <sup>
     <a ref-type="bibr" rid="CR19">19</a>
    </sup>
   </td>
   <td>PD and subjects diagnosed with other causes of parkinsonism/tremor</td>
   <td>Sanger sequencing; SNP genotype</td>
   <td>Motor and nonmotor assessments</td>
  </tr>
  <tr>
   <td>PROPARK (Netherlands) 
    <sup>
     <a ref-type="bibr" rid="CR20">20</a>
    </sup>
   </td>
   <td>PD</td>
   <td>Targeted sequencing or whole exome sequencing</td>
   <td>Motor and nonmotor assessments</td>
  </tr>
  <tr>
   <td>LABS-PD (USA, Canada) 
    <sup>
     <a ref-type="bibr" rid="CR21">21</a>
    </sup>
   </td>
   <td>PD and HC</td>
   <td>Targeted sequencing</td>
   <td>Motor and nonmotor assessments, biomarkers, imaging data</td>
  </tr>
  <tr>
   <td>PICNICS (UK) 
    <sup>
     <a ref-type="bibr" rid="CR22">22</a>
    </sup>
   </td>
   <td>PD</td>
   <td>Sanger sequencing</td>
   <td>Motor and nonmotor assessments</td>
  </tr>
  <tr>
   <td>DATATOP (USA, Canada) 
    <sup>
     <a ref-type="bibr" rid="CR23">23</a>
    </sup>
   </td>
   <td>PD</td>
   <td>Targeted sequencing</td>
   <td>Motor and nonmotor assessments</td>
  </tr>
  <tr>
   <td>PDBP 
    <sup>
     <a ref-type="bibr" rid="CR24">24</a>
    </sup>
   </td>
   <td>PD and HC</td>
   <td>NeuroX genotyping</td>
   <td>Motor and nonmotor assessments</td>
  </tr>
  <tr>
   <td>Penn-Udall (USA)</td>
   <td>PD</td>
   <td>Targeted sequencing</td>
   <td>Motor and nonmotor assessments</td>
  </tr>
  <tr>
   <td>PPMI (USA, Europe) 
    <sup>
     <a ref-type="bibr" rid="CR25">25</a>
    </sup>
   </td>
   <td>PD, SWEED, and HC</td>
   <td>Whole exome sequence</td>
   <td>Motor and nonmotor assessments, CSF biomarkers, neuroimaging data</td>
  </tr>
  <tr>
   <td>BioFIND (USA) 
    <sup>
     <a ref-type="bibr" rid="CR26">26</a>
    </sup>
   </td>
   <td>PD and HC</td>
   <td>Whole genomic sequence of the GBA1 gene</td>
   <td>Motor and nonmotor assessments, biospecimen data</td>
  </tr>
  <tr>
   <td>IPDGC (worldwide) 
    <sup>
     <a ref-type="bibr" rid="CR30">30</a>
    </sup>
   </td>
   <td>PD and HC</td>
   <td>NeuroX genotyping</td>
   <td>Not specified</td>
  </tr>
 </tbody>
 <tfoot>
  <p>
   <i>CamPaIGN</i> Cambridgeshire Parkinson’s incidence from General Practitioner to Neurologist, 
   <i>DIGPD</i> Drug Interaction with Genes in Parkinson’s Disease, 
   <i>EMBL-EMI</i> The European Bioinformatics Institute, 
   <i>HBS</i> Harvard Biomarkers Study, 
   <i>IPDGC</i> International Parkinson’s Disease Genomics Consortium, 
   <i>LABS-PD</i> Longitudinal and Biomarker Study in Parkinson’s disease, 
   <i>NCBI</i> The National Center for Biotechnology Information, 
   <i>PD</i> Parkinson’s disease, 
   <i>PDPB</i> Parkinson’s Disease Biomarkers Program, 
   <i>Penn-Udall</i> Morris K Udall Parkinson’s Disease Research Center of Excellence cohort, 
   <i>PICNICS</i> Parkinsonism: Incidence, Cognition and Non–motor heterogeneity in Cambridgeshire, 
   <i>PPMI</i> Parkinson’s Progression Marker Initiative, 
   <i>PreCEPT</i> Parkinson Research Examination of CEP–1347 Trial, 
   <i>PROPARK</i> PROFIling PARKinson’s disease, 
   <i>SWEDD</i> scans without evidence of dopaminergic deficit. 
  </p>
 </tfoot>
</table>
